Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Markus Cornberg(Medizinische Hochschule Hannover), Heiner Wedemeyer(Medizinische Hochschule Hannover), Marc G. Ghany(National Institute of Diabetes and Digestive and Kidney Diseases), Patrick Kennedy(Queen Mary University of London), Norah A. Terrault(University of Southern California), Stephen Locarnini, George Papatheodoridis(National and Kapodistrian University of Athens), Jake T. Liang(National Institutes of Health), Kyong‐Mi Chang(Philadelphia VA Medical Center), Stephanie Buchholz, Harry L.A. Janssen(Erasmus MC), Jordan J. Feld(University Health Network), Marı́a Buti(Vall d'Hebron Hospital Universitari), Silke Schlottmann, Fabien Zoulim(Hôpital de la Croix-Rousse), Carlo Ferrari(University of Parma), Maurizia Rossana Brunetto(University of Pisa), Thomas Berg(Leipzig University of Applied Sciences), Mala K. Maini(California Institute of Technology), Su Wang(Rutgers, The State University of New Jersey), Poonam Mishra, Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Geoffrey Dusheiko, Anna Suk‐Fong Lok(University of Michigan), Maura Dandri(Universität Hamburg), Jörg Petersen, Henry Lik‐Yuen Chan(Radiant Research (United States))
Cited by 364
Related Papers
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
|Hepatology|2008|3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
|The Lancet Neurology|2020|1.4k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k